(616 Kb) -

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies . (616 KB)

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). : A major finding was that 41% of